Merck KGaA expands its deal with Pfizer/BioNTech with an eye on a key vaccine manufacturing bottleneck

Nicole DeFeudis

Editor

Conner Mitchell

As Pfizer and BioNTech’s vaccine delivery runs behind schedule in the EU, Merck KGaA is aiming to boost production by accelerating its supply of custom …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Merck KGaA expands its deal with Pfizer/BioNTech with an eye on a key vaccine manufacturing bottleneck

Nicole DeFeudis

Editor

Conner Mitchell

Sign up to read this article for free.

Anne Wojcicki and Regeneron set to duke it out in restarted 23andMe auction

FDA's Prasad explains rationale behind pausing Valneva's chikungunya vaccine in seniors

Biotech ranks as China’s best shot to surpass US in emerging tech, report finds

A decade after its ill-fated $40.5B megadeal, Teva pivots from generics to innovation

Regeneron plans to buy 23andMe for $256M

Cytiva and EurekaBio form strategic partnership to advance lentiviral vector manufacturing for cell and gene therapy ...

Mer­ck KGaA ex­pands its deal with Pfiz­er/BioN­Tech with an eye on a key vac­cine man­u­fac­tur­ing bot­tle­neck

Editor

Sign up to read this article for free.

Merck KGaA expands its deal with Pfizer/BioNTech with an eye on a key vaccine manufacturing bottleneck